experimental group:Sintilimab+bevacizumab

Sintilimab in combination with bevacizumab as second-line therapy for patients with advanced/recurrent endometrial cancer: a single-arm, open-label exploratory study

Sintilimab in combination with bevacizumab as second-line therapy for patients with advanced/recurrent endometrial cancer: a single-arm, open-label exploratory clinical study